HHlevo-M Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, formulated to provide effective relief from allergic conditions. Levocetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, rhinorrhea, nasal itching, and urticaria without causing significant sedation. Montelukast is a leukotriene receptor antagonist that blocks the action of leukotrienes, inflammatory mediators involved in allergic responses and bronchoconstriction. The synergistic action of these two agents makes HHlevo-M Tablet particularly beneficial in managing allergic rhinitis, chronic urticaria, and asthma. This combination improves symptom control by addressing both histamine-mediated and leukotriene-mediated pathways, enhancing patient compliance through once-daily dosing. HHlevo-M is indicated for patients requiring comprehensive allergy management, especially those with concomitant respiratory symptoms. It is generally well tolerated, with a low incidence of adverse effects such as headache, fatigue, or gastrointestinal disturbances. Caution is advised in patients with hepatic or renal impairment, and it should be used under medical supervision, particularly in pediatric and elderly populations. HHlevo-M Tablet offers an effective therapeutic option for improving quality of life in individuals suffering from allergic disorders.